Orthocell (ASX:OCC) posted revenue of AU$3.2 million for the quarter ended Dec. 31, 2025, up 45% on the previous corresponding period, according to a Tuesday filing with the Australian bourse.

Revenue for the period also represents a 7% increase over the previous quarter and the seventh consecutive quarter of record revenue, the filing said.

The increase was mainly due to increased market penetration, particularly Australia, as well as initial financial contributions from early Remplir nerve repair product surgical cases in the US, per the filing.

Shares rose past 1% in morning trade Tuesday.